Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Efforts to manufacture the leading candidates, at risk, are gearing up
02-Jul-2020 -
Pfizer Inc. and BioNTech SE announced preliminary U.S. data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at ...
coronaviruses
mRNA vaccines
SARS-CoV-2
+2